Private Equity Gastroenterology: Top Firms in 2026

Key Facts: Private Equity in Gastroenterology

• Approximately 68 private equity-backed GI groups were active as of 2021, representing 28% year-over-year growth, according to a Fraser Healthcare and Spherix Global Insights joint report.
• Gastroenterology has the highest PE penetration of any physician specialty: 13.1% of gastroenterologists practice within a PE-backed group as of 2025, according to peer-reviewed research.
• Annual deal volume dropped from 26 transactions in 2022 to 13 in 2023, signaling a maturing market where individual deals are larger but fewer.
• The two dominant platforms are GI Alliance (approximately 700 physicians across 16 states) and Gastro Health (360-plus physicians across eight states).
• Cardinal Health acquired a $2.8 billion majority stake in GI Alliance in late 2024, establishing corporate strategics as a credible exit pathway alongside secondary PE recapitalizations.
• GI practices with three to nine physicians declined 41% over the past decade, while practices with 500-plus physicians grew 66%, according to 2025 industry data.
• Medicare reimbursement for GI procedures has fallen more than 25% in inflation-adjusted terms over 20 years, making independent practice increasingly difficult to sustain financially.

GI Sector Overview: Market Dynamics and Investment Model

Private equity investment in gastroenterology targets a specific model: acquiring independent GI physician practices and ambulatory surgery centers (ASCs), then consolidating them under a management services organization (MSO). The MSO handles billing, contracting, and operations while physicians retain clinical control. Unlike venture capital or growth equity strategies that target emerging companies, PE investment in GI focuses on acquiring established practices with proven procedural revenue from colonoscopies and endoscopy, combined with an aging population driving structural demand growth.

Declining Medicare reimbursement rates, rising practice operating costs, and MACRA quality-reporting mandates have made independent operation increasingly unviable. This has accelerated physician willingness to partner with PE fund managers. The sector launched in 2016 when Audax Group founded Gastro Health in Florida, creating the first major PE-backed GI platform and establishing the playbook the entire industry would follow.

Seven of the ten subsequent major platforms emerged after May 2019. By 2021, more than 10 individual GI deals closed in a single year. The projected shortage of 1,400 to 1,500 gastroenterologists creates a supply-demand imbalance that further strengthens platform pricing power with commercial payers.

Geographic activity is concentrated in Florida, Georgia, Texas, Virginia, and Pennsylvania, where major platforms established regional dominance first. National platforms have since expanded across these hubs: GI Alliance covers 16 states, Gastro Health operates across eight. Significant whitespace remains in unconsolidated regional markets outside major metro areas, sustaining acquisition competition even as total deal count has declined.

The 2024-2025 entry of corporate strategic buyers (Optum SCA Health acquiring US Digestive Health, Cardinal Health acquiring a majority stake in GI Alliance) signals that the sector has matured enough to attract Fortune 500 healthcare acquirers as exit buyers.

Firm Comparison at a Glance

The table below covers the leading PE-backed GI platforms and their PE sponsor firms, distinguishing between platforms (the operating entities that employ or affiliate physicians) and PE sponsors (the fund managers that own and direct platform strategy). No individual AUM figures are publicly disclosed for these entities.

The clearest differentiator across these entities is the platform versus PE sponsor distinction. Physicians evaluating partnership options interact with the platform (GI Alliance, Gastro Health, One GI), not the PE sponsor directly, though sponsor strategy shapes governance, fee structures, and exit timelines.

Top Picks by Investment Strategy

Largest Platform by Physician Count: GI Alliance operates with approximately 700 physicians across 16 states. Its physician-majority ownership structure (established in 2022) and Cardinal Health's $2.8 billion majority stake acquisition in late 2024 (the largest disclosed transaction in GI PE history) validate the model for the entire sector.

Broadest Geographic Reach: Gastro Health spans 360-plus physicians across Florida, Alabama, Maryland, Ohio, Virginia, Massachusetts, and Washington State. Audax Group's 2016 founding investment created the GI PE playbook, and OMERS' 2021 secondary acquisition marked the first institutional pension fund entry into the US GI platform market.

Southeast Regional Leader: United Digestive, Atlanta-based, has completed two recapitalizations demonstrating durable value creation across multiple PE hold periods. Kohlberg & Company's March 2023 secondary acquisition of the Frazier Healthcare-backed platform signals continued investor appetite for mature regional consolidators.

Fastest-Growing Platform: One GI (backed by Webster Equity Partners) quadrupled its physician count and entered six states within two years of acquisition. The firm closed four add-ons in 2023 alone across Virginia, Tennessee, and Kentucky.

Best Corporate Exit Story: US Digestive Health (Amulet Capital Partners) assembled 250-plus providers across 40 sites, including 24 ambulatory surgery centers, before Optum SCA Health acquired it in early 2025. The depth of its ASC infrastructure illustrates how ancillary revenue builds exit valuation.

Physician Autonomy Model: Capital Digestive Care remains 100% physician-owned, with 70-plus physicians in the Washington DC metro. Its 2019 decision to partner with an MSO rather than sell equity to PE is now studied as an alternative model for practices that want operational support without surrendering ownership.

Most Focused GI-Specific PE Sponsor: Webster Equity Partners has exclusively committed to One GI's high-growth buy-and-build thesis. Leveraging its healthcare services focus (established 2003), the firm executes rapid multi-state expansion through disciplined bolt-on acquisition.

Top Firms in Detail

GI Alliance

The largest physician-led gastroenterology MSO in the United States, GI Alliance operates with approximately 700 physicians across 16 states. That scale gives it significant leverage in commercial payer contracting that smaller independent practices cannot replicate. What distinguishes GI Alliance is its governance evolution: by 2022, physicians held approximately 85% equity stake and voting control of the MSO board, creating a physician-majority structure that most PE-backed practices cannot claim.

That governance differentiation proved commercially valuable. Cardinal Health's $2.8 billion majority stake acquisition in late 2024 (the largest disclosed transaction in GI PE history) validated the model for the entire sector. Texas-based, with add-ons including Arizona Digestive Health (2019) and Connecticut GI (2023), GI Alliance represents the endpoint that most PE-backed platforms aspire to reach.

Gastro Health

Gastro Health's significance extends beyond its current scale of 360-plus physicians across eight states: it created the gastroenterology PE sector. Audax Group's 2016 formation of a Florida-based GI platform was the first of its kind, establishing the MSO model and add-on acquisition playbook that every subsequent entrant has replicated. The 2021 OMERS secondary acquisition marked two firsts: the initial sale of a PE-backed GI platform to an institutional investor, and the first participation of a Canadian pension fund in this asset class.

Miami-headquartered, Gastro Health has since expanded beyond its Southeast origins into Maryland, Ohio, Virginia, Massachusetts, and Washington State. The trajectory demonstrates that regional platforms can achieve national scale through systematic bolt-on acquisition.

United Digestive

Atlanta-based United Digestive is the clearest evidence that GI platforms can generate returns across multiple investment cycles. Frazier Healthcare Partners built the Southeast-focused platform initially; Kohlberg & Company completed a secondary recapitalization in March 2023, acquiring the platform and injecting new capital for continued regional expansion. The 2023 add-on of the Gastroenterology Group of Naples extended United Digestive's Florida footprint during the same period.

For GI practice owners evaluating what happens after the first PE partnership cycle, United Digestive's two-recapitalization track record is the most instructive data point available in the sector.

One GI (Webster Equity Partners)

One GI's expansion pace sets a benchmark no other GI platform has matched: physician count quadrupled within two years of Webster Equity Partners' acquisition, expanding into six states through sustained add-on activity. In 2023 alone, One GI closed four transactions: Gastroenterology Associates of Tidewater in Virginia, TransSouth in Tennessee, Gastroenterology Associates PC in Virginia, and Skyline Gastroenterology and Endoscopy in Kentucky.

Webster Equity Partners, a healthcare services-focused PE firm founded in 2003, brought an explicit buy-and-build investment thesis to GI. The firm prioritizes physician count growth and geographic coverage over near-term integration. Practices in Virginia, Tennessee, and Kentucky markets that remain partially unconsolidated will find One GI among the most actively acquisitive platforms in those regions.

US Digestive Health

US Digestive Health, backed by Amulet Capital Partners, illustrates what a mature GI platform looks like at the moment of corporate strategic exit. At acquisition by Optum SCA Health in early 2025, the Pennsylvania-based platform had assembled 250-plus providers across 40 sites, with 24 ambulatory surgery centers embedded in the platform. Blair Gastroenterology Associates joined the platform in 2023 among its final add-ons before exit.

The transaction is significant not just as a liquidity event for Amulet but as a template. It demonstrates that a mid-market GI platform with strong ASC infrastructure can attract a UnitedHealth Group subsidiary as a strategic acquirer, creating an exit pathway outside the traditional secondary PE recapitalization.

Capital Digestive Care

Capital Digestive Care occupies a unique position in the GI market: a 100% physician-owned practice with 70-plus gastroenterologists in the Washington DC metropolitan area that has navigated the PE era without selling equity. In 2019, the practice partnered with Physicians Endoscopy as an MSO services provider rather than accepting a direct PE acquisition offer. Physicians Endoscopy was subsequently acquired by Optum SCA Health, meaning Capital Digestive Care's physicians gained access to large-system operational support while retaining full practice ownership.

The model demonstrates that MSO partnership and physician ownership are not mutually exclusive. The subsequent corporate acquisition of their MSO partner illustrates how quickly the affiliation landscape can shift even for practices that choose independence.

Webster Equity Partners

Webster Equity Partners is the PE sponsor most exclusively committed to gastroenterology among the active investors in this market. The firm's healthcare services focus, established in 2003, has found its sharpest expression in One GI's buy-and-build expansion across the Southeast and Mid-Atlantic. Webster's investment thesis prioritizes high-impact growth in companies delivering high-quality care, a framing that aligns with physician-led governance structures rather than aggressive top-down management.

For GI practices evaluating PE sponsors rather than platforms, Webster's track record in One GI (geographic expansion, physician count growth, sustained deal activity through 2023) provides the most direct evidence of its GI-specific capabilities.

Kohlberg & Company

Kohlberg & Company's role in GI PE is specialized and instructive: the firm is a secondary buyout specialist that acquired United Digestive in March 2023 after Frazier Healthcare Partners had completed the initial platform-building phase. Secondary acquirers like Kohlberg target platforms that have already proven their operating model and geographic strategy, then deploy new capital for the next phase of growth.

For physicians already inside a PE-backed GI practice approaching the end of their sponsor's hold period, Kohlberg's acquisition of United Digestive is a concrete example of what the "second bite" looks like: a new sponsor, refreshed capital, and an extended timeline before the next exit event.

Frazier Healthcare Partners

Frazier Healthcare Partners built United Digestive from its origins as a Southeast-focused platform before exiting through the Kohlberg & Company secondary. As a healthcare-dedicated PE firm, Frazier brought sector-specific expertise to the initial platform formation phase. The firm identified a Georgia-based regional practice as the right foundation for Southeast consolidation and executed the add-on strategy that made the secondary recapitalization attractive to a buyer like Kohlberg.

Frazier represents the category of healthcare-specialist PE firms whose deep sector knowledge creates better outcomes in platform formation than generalist fund managers entering GI for the first time.

Investment Trends and Capital Flows

Corporate Strategics Replace PE as Exit Buyers

The two largest GI transactions of 2024-2025 were executed by corporate healthcare companies, not PE funds: Cardinal Health's $2.8 billion majority stake in GI Alliance and Optum SCA Health's acquisition of US Digestive Health. This signals a structural shift. GI platforms have grown large enough to serve strategic purposes for Fortune 500 healthcare organizations, creating an exit pathway that competes directly with the secondary PE recapitalization. Uncommitted capital (dry powder) from PE funds remains available, but corporate buyers are now setting the valuation ceiling.

Ancillary Service Integration as Value Driver

In-house ambulatory surgery centers, pathology services, anesthesiology, infusion therapy, and weight management programs (including GLP-1 protocols) are no longer optional enhancements. They are the primary mechanism through which GI platforms offset declining Medicare reimbursement. US Digestive Health's 24 ASCs across 40 sites exemplify how ancillary revenue diversity attracts corporate strategic buyers. Platforms that have not prioritized ancillary buildout face compression in EBITDA multiples at exit.

Geographic Whitespace and Regional Consolidation

Many parts of the United States (particularly secondary cities and rural markets) remain largely untouched by PE consolidation, representing the primary source of deal flow for platforms like One GI and United Digestive. Add-on acquisitions in these whitespace markets continue even as total annual deal count declined from 26 in 2022 to 13 in 2023. Smaller independent practices in underserved markets face the same reimbursement pressures and MACRA compliance burdens as their urban counterparts, but with fewer resources to absorb them.

Colorectal Cancer Screening Expansion

The 2021 guideline update lowering colorectal cancer screening to age 45 materially expanded the addressable colonoscopy volume for every GI practice in the country. Combined with rising colorectal cancer incidence and an aging US population, this structural demand growth reinforces the long-term investment thesis for GI platforms regardless of near-term deal cycle softness. A projected shortage of 1,400 to 1,500 gastroenterologists means existing platforms face inelastic procedure demand with limited new physician supply.

Regulatory and Antitrust Headwinds

Oregon signed strict healthcare PE oversight legislation into law in 2025, one of the most stringent state-level regulatory frameworks in the country. Pennsylvania's House passed legislation expanding review of medical practice acquisitions the same year. The FTC, DOJ, and HHS jointly solicited public input on corporate healthcare ownership in spring 2024 and received more than 2,000 comments. Fifteen states now require notification for proposed healthcare mergers and acquisitions. These developments add transaction complexity and legal due diligence burden, though deal activity has continued.

How to Evaluate PE Investors in Gastroenterology

Clinical autonomy protection is the most consequential term in any PE partnership agreement, and it must be contractually explicit. Vague language about "physician-led culture" without enforceable governance rights (board seats, voting control on clinical staffing decisions, and MSO management agreement boundaries) is a significant red flag. Request the specific operating agreement language that defines which decisions require physician approval versus which are reserved for the MSO.

Management fee structures require equally careful scrutiny. PE firms in gastroenterology typically extract 25 to 35% of future physician income through management fees, a practice sometimes called "the scrape." Understand exactly how your compensation formula changes post-acquisition: the gap between the upfront equity payment and long-term income trajectory is the real economic trade-off in any PE transaction.

Hold periods in GI PE run three to seven years, with most sponsors targeting four to six. Ask specifically about the PE sponsor's track record on secondary recapitalizations within gastroenterology, not just healthcare broadly. Platforms that have completed a second recapitalization (GI Alliance, Gastro Health, United Digestive) provide concrete evidence that physician equity rollover value survives into subsequent ownership cycles.

Track record evaluation should include physician retention rates at existing portfolio companies. High turnover after acquisition is among the clearest signals of governance or compensation failures. Request direct references from physician partners at two to three practices the platform has already integrated, and ask whether clinical decision-making autonomy was maintained.

Key red flags to watch: no physician representation on the MSO board; the PE sponsor controls all carrier contract negotiations without physician input; vague or absent clinical autonomy protections in the operating agreement; management fees that permanently reduce income with no performance-linked offset; a PE sponsor with no prior GI-specific deal experience.

Payer mix and contracting leverage are tangible benefits that justify platform affiliation for many practices. Larger platforms negotiate materially higher commercial reimbursement rates than independent practices, a real economic benefit that partially offsets management fees. Evaluate whether the platform's existing contracts in your market reflect this leverage.

Which Firm Fits Your Needs?

GI practice owners evaluating a full sale or significant equity transaction should start with GI Alliance and Gastro Health. Both offer established ancillary infrastructure, validated corporate exit pathways (Cardinal Health, OMERS), and governance models with documented physician leadership. The scale of both platforms means stronger commercial payer leverage than any mid-market alternative, a concrete financial benefit that materializes immediately post-affiliation.

Practices in unconsolidated regional markets outside the major metro areas should look carefully at One GI and United Digestive. One GI's Webster Equity Partners-backed buy-and-build thesis has targeted exactly this type of market (secondary cities in Virginia, Tennessee, and Kentucky) with four 2023 add-ons demonstrating active acquisition appetite. United Digestive's Southeast regional focus similarly reflects a strategy built on geographic consolidation rather than coastal market saturation.

Physicians who want operational support without surrendering ownership should study Capital Digestive Care's MSO partnership model closely. The Washington DC practice's 2019 decision to partner with an MSO rather than sell equity created a structure that has preserved 100% physician ownership through multiple changes in the MSO's corporate parentage. Limited partners and institutional investors evaluating exposure to GI PE as an asset class should note that secondary PE recapitalizations (Kohlberg acquiring United Digestive) and corporate strategic exits (Optum, Cardinal Health) both represent realized liquidity events, validating the asset class across multiple exit channels.

Methodology

This guide covers gastroenterology private equity based on peer-reviewed research (2025), transaction data from PE industry M&A databases, platform disclosures, and market analyses from healthcare investment banking advisors covering GI physician practice consolidation through early 2026. Firm profiles are limited to entities with documented transaction histories, physician counts, or geographic footprints available from public sources. No individual fund AUM figures are disclosed by any of the featured firms; the assets under management column was accordingly omitted from the comparison table. Geographic and deal data reflect transactions through early 2025. Regulatory information reflects state-level legislation as enacted or passed through early 2026.